ID: ALA5279831

Max Phase: Preclinical

Molecular Formula: C22H18FN3

Molecular Weight: 343.41

Associated Items:

Representations

Canonical SMILES:  Fc1ccc2ncnc(NCCc3cccc(-c4ccccc4)c3)c2c1

Standard InChI:  InChI=1S/C22H18FN3/c23-19-9-10-21-20(14-19)22(26-15-25-21)24-12-11-16-5-4-8-18(13-16)17-6-2-1-3-7-17/h1-10,13-15H,11-12H2,(H,24,25,26)

Standard InChI Key:  JVMGKKWNIHYGJH-UHFFFAOYSA-N

Associated Targets(Human)

PC-9 1037 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 343.41Molecular Weight (Monoisotopic): 343.1485AlogP: 5.09#Rotatable Bonds: 5
Polar Surface Area: 37.81Molecular Species: NEUTRALHBA: 3HBD: 1
#RO5 Violations: 1HBA (Lipinski): 3HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 3.99CX LogP: 5.30CX LogD: 5.30
Aromatic Rings: 4Heavy Atoms: 26QED Weighted: 0.55Np Likeness Score: -1.12

References

1. Elsocht M, Giron P, De Grève J, Ballet S..  (2023)  Second generation Spautin-1 analogues targeting EGFR-mutant non-small cell lung cancer cells.,  79  [PMID:36410591] [10.1016/j.bmcl.2022.129066]

Source